- Microdosing Collective
- Posts
- Summit Panel: Legalizing Microdosing ⚖️
Summit Panel: Legalizing Microdosing ⚖️
Graham Boyd and Ismail Lourido Ali on where the law stands, and what comes next

Can you legally microdose in America? The honest answer is: it depends where you're standing.
About 10 million American adults microdosed in the past year, according to RAND's 2025 survey. Almost none of them did it under a law written with microdosing in mind.
Changing that is why the Microdosing Collective exists. We're a nonprofit, and our work is made possible by readers who give.
At the Microdosing Summit in Austin, our co-founder Joshua Kappel sat down with two of the people who have done the most to change that. Between them they have written ballot measures, run campaigns, and funded the research behind most of the psychedelic laws on the books today.
Graham Boyd, Executive Director and Co-Founder of the Psychedelic Science Funders Collaborative (PSFC), and before that a leading strategist behind cannabis legalization across the country
Ismail Lourido Ali, Co-Executive Director of MAPS
Moderated by Joshua Kappel, Co-Founder of the Microdosing Collective, founding partner at Vicente LLP, and one of the drafters of Colorado's Natural Medicine Health Act
Here are five takeaways from the conversation. 👇
#1: The legal term is "patchwork" ⚖️
"I believe the formal legal term is patchwork." - Ismail Lourido Ali
Psychedelics are still illegal under federal law. Below that, a few states have built regulated programs. Oregon and Colorado have gone furthest: Josh said about 28,000 people have been through their programs combined. New Mexico is aiming to open its medical program by the end of this year. Ismail counted about two dozen cities and counties that have made personal use a low priority for police.
Graham pointed out the catch. Police in many places have mostly stopped chasing personal use, but because it is still illegal it is "not always as safe" and "more stigmatized." The early fight was about keeping people out of jail. In his words, the next one is "really more about safety and access."
What you can do: Know where you live. Whether something carries criminal penalties really does depend on your state and city, and "decriminalized" is not the same as "legal."
#2: There is no one program to rule them all 🛤️
"There is no one program to rule them all." - Ismail Lourido Ali
Ismail described the system he hopes to build as one with "a lot of on-ramps and a lot of off-ramps." Some people will never trust a doctor's office again. Others will never sit with a healer. A good system has a way in for both, from growing and sharing at home, to regulated adult use, to professional care for people with more complex health needs.
Graham added a warning about the federal route. He believes FDA approval of psychedelic medicines is coming soon and will be "revolutionary." But he expects that a year or two later many people will say, "Wait a minute, I thought it was going to be better than this," once they find access limited to people with the right diagnosis, the right insurance and an approved clinic nearby. That is where state programs, and microdosing, come in.
#3: Meet people where they are 🗣️
Graham told the story of cannabis. Early campaigns tried to argue voters out of their views with research and doctors, and they lost. What worked was listening first. The first successful ad showed a mother in a coffee shop saying, "It's not that I like marijuana, but what we're doing right now doesn't work."
He applied the same lesson to Massachusetts, where a 2024 psychedelics ballot measure lost. Graham believes it would have passed without the provision allowing people to grow mushrooms at home: "I hate it that we made the wrong call there."
Josh added the other half. Voters in the middle can be moved by stories, and most people have never heard one about microdosing. Ismail agreed that arguing people out of strongly held beliefs rarely works. It is better, he said, to give them room to get there in their own time.
What you can do: Be the story. A calm, honest conversation with one person outside the bubble does more than a heated argument with ten.
#4: New York could be a first 🗽
New York's Medical Psilocybin Act (A2142-A), sponsored by Assembly Member Amy Paulin, would create state-licensed psilocybin care for patients with a medical diagnosis. Graham explained what makes it new: a narrow pathway for people with cluster headaches, whose doctor could authorize them to take psilocybin home, with a supply covering several months that is tracked along the way.
"It's a baby step, but the first step towards saying to the world, microdosing is legitimate." - Graham Boyd
The bill hasn't passed yet. It is in the Assembly Health Committee, where it was last amended in May.
#5: Don't build the next cannabis industry 🏪
The sharpest question from the audience came from someone who works with people struggling with cannabis use. What will psychedelics do differently?
Graham said it is the thing most on his mind. He worries most about a world of "massive consumer product companies with large marketing budgets" pushing microdosing on everyone. Ismail said he has become "pretty much completely against advertising for anything psychoactive," and offered a reminder from history: ending Prohibition "ended the organized crime related to alcohol sales, but it did not end alcoholism."
Josh closed the session with what may be the heart of MC's work: "the problem actually isn't the substances, it's our relation to the substances."
📚 Go Deeper: The Wider View
What the regulated programs look like up close. Researchers called 15 of Oregon's licensed psilocybin centers posing as a client on an antidepressant. Screening was careful, but none allowed take-home dosing, and sessions cost a median of about $1,900, with no insurance accepted. Read the study (Health Affairs Scholar, 2026)
A harder look at Oregon's model. OPB reports that about a third of Oregon's licensed service centers have closed, as high license fees and session prices squeeze operators. Listen or read (OPB, Jan 2026)
A different view from inside the movement. Not every psychedelic advocate backed Massachusetts' 2024 measure. Some grassroots groups opposed it, arguing it would make care costly and corporate. Read the reporting (BINJ, 2024)
A call to slow the hype. Researcher Neşe Devenot argues that overselling psychedelics understates their risks, and that honest, nuanced harm reduction makes the field stronger. Read the essay (Harvard Law School's Petrie-Flom Center, 2024)
Read the New York bill yourself. A2142-A on the NY Senate site
New to microdosing? Start with our free guide, The Microdosing Manual.
💬 Where do you think microdosing should fit: medicine, wellness, or something new? Reply and let us know!

🍄 Join our Giving Circle
Conversations like this one are what the Microdosing Collective does all year: free education, research through our new global research alliance, and a voice for people who microdose wherever policy is being shaped. On Giving Tuesday, December 1, we'll ask for your help to keep it going. If you'd like to start now, become a monthly supporter.
Our Giving Circle makes it easy to support microdosing legalization through small, consistent contributions. We’re incredibly grateful for your support as we continue growing this movement through advocacy, education, research, and community.
- With love from team Microdosing Collective 🍄
Was this email forwarded? Subscribe to get the next one delivered right to you!
DISCLAIMER: This newsletter is intended for educational and informational purposes only and should not be considered a replacement for professional medical advice. Always consult your healthcare provider before making changes. The Microdosing Collective does not promote the use of any illegal substance. Please be aware that the use, possession, and distribution of psychedelic substances are illegal in many countries and could lead to legal consequences.
Reply